Clinical Trials Browser

Phase 3 × Endocrine × 1 year × Clear all

NCT06784752 2026-04-16

NETTER-3

Phase 3 Recruiting

EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT06881992 2026-04-14

Tumor HI

Phase 3 Recruiting

EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00569127 2026-04-13

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Phase 3 Active not recruiting

427 enrolled 17 charts

Neuroendocrine Tumors

NCT03375320 2026-04-13

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 3 Active not recruiting

298 enrolled 14 charts 3 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03049189 2026-04-06

COMPETE

Phase 3 Active not recruiting

324 enrolled 15 charts

Neuroendocrine Tumors

NCT05477576 2026-03-30

ACTION-1

Phase 3 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT07087054 2026-03-10

CAREFNDR

Phase 3 Recruiting

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT04810091 2026-03-09

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

Phase 3 Active not recruiting

79 enrolled 24 charts

Neuroendocrine Tumors

NCT05918302 2026-03-06

LEVEL

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

NCT03194893 2026-02-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Phase 3 Active not recruiting

EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

NCT06822751 2026-02-17

FOMUTI

Phase 3 Not yet recruiting

Cystitis, Prostatitis, Urinary Tract Infections, Multiple Endocrine Neoplasia Type 1

NCT06937905 2026-02-11

TARLANEC

Phase 3 Recruiting

Carcinoma, Neuroendocrine

NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

Phase 3 Recruiting

CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

NCT03972488 2026-01-21

NETTER-2

Phase 3 Active not recruiting

226 enrolled 14 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04940052 2025-12-02

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Phase 3 Active not recruiting

EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

NCT03872401 2025-11-10

VESALIUS-CV

Phase 3 Completed

12,301 enrolled

Coronary Disease, Multiple Endocrine Neoplasia Type 1

NCT05050942 2025-11-06

SORENTO

Phase 3 Active not recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT03690388 2025-09-25

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Phase 3 Active not recruiting

187 enrolled 13 charts 2 FDA

EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT00410761 2025-09-24

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Phase 3 Completed

331 enrolled 15 charts

EndocrineHead & Neck

Familial medullary thyroid carcinoma, Thyroid Neoplasms, Carcinoma, Medullary

NCT07185672 2025-09-22

PReCedeNT

Phase 3 Recruiting

Neuroendocrine Tumors

NCT04919226 2025-09-10

COMPOSE

Phase 3 Active not recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05387603 2025-09-10

START-NET

Phase 3 Recruiting

Neuroendocrine Tumors

NCT05459844 2025-09-05

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Phase 3 Active not recruiting

Neuroendocrine Tumors

NCT06878664 2025-09-02

RIALTO

Phase 3 Recruiting

Neuroendocrine Tumors

NCT03697109 2025-07-16

GRACE

Phase 3 Completed

152 enrolled 28 charts

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Pituitary ACTH Hypersecretion

NCT02010957 2025-06-10

FAMIAN

Phase 3 Terminated

Adrenal Gland Neoplasms

NCT02288962 2025-06-08

Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas

Phase 3 Active not recruiting

Adenoma, Pituitary Neoplasms

NCT06091748 2025-06-03

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Phase 3 Recruiting

EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

NCT02840149 2025-05-15

SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors

Phase 3 Completed

Neuroendocrine Tumors

NCT02246127 2025-05-11

SEQTOR

Phase 3 Completed

141 enrolled 27 charts

Neuroendocrine Tumors